Abcam, ab232629, Anti-Firefly Luciferase antibody [EPR17790] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal LUCI antibody. Carrier free. Suitable for Flow Cyt, ICC/IF, WB and reacts with Firefly samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR17790,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Firefly,
Applications:WB, Flow Cyt, ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab232629 is the carrier-free version of
ab185924
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Firefly luciferase also known as luc assay or luciferase protein is an enzyme that catalyzes the oxidation of luciferin resulting in bioluminescence. This protein has a molecular mass of approximately 61 kDa and is responsible for the characteristic glow of fireflies. The luciferase expression occurs mainly in the light-producing organs of fireflies such as in the insect Photinus pyralis where it plays an important role in light emission.
Biological function summary
Firefly luciferase converts chemical energy into light making it valuable for various biological applications as a reporter gene. It participates in the formation of a complex with its substrates luciferin and ATP resulting in the production of a photon. This enzyme is widely used in molecular and cellular biology experiments to monitor gene expression and study protein-protein interactions due to its luminescent properties.
Pathways
Firefly luciferase functions in the bioluminescent pathway involving the conversion of luciferin to oxyluciferin and light emission. It interfaces with ATP a universal energy carrier which highlights its integration into the cellular energy systems. Firefly luciferase is similar to other oxidative enzymes though it is not directly involved with metabolic pathways like the TCA cycle or glycolysis.
Researchers often utilize firefly luciferase as a tool in tumor studies or infectious disease models. Its luminescence aids in imaging and tracking biological processes in real-time. While firefly luciferase itself is not directly associated with specific diseases the use of firefly agents allows researchers to study disease outcomes assess therapeutic efficacy and understand gene expression profiles related to cancer and viral infections often in connection with proteins such as p53 in cancer research.